The European Food Safety Authority (EFSA), the European Centre for Disease Control and Prevention (ECDC) and the European Medicines Agency (EMEA) have published today a joint Scientific Report on meticillin resistant Staphylococcus aureus (MRSA) in livestock, pets and foods.
Following a request from the European Commission, EFSA's Panel on Biological Hazards and ECDC concluded that food-producing animals such as pigs, veal calves and broiler chickens often carry without symptoms a specific strain of MRSA called CC398. However, while food may be contaminated by MRSA there is currently no evidence that eating or handling contaminated food can lead to an increased health risk for humans. The report also noted that people in contact with live animals that carry the CC398 strain of MRSA could be at risk of infection. This specific strain of MRSA has been associated, albeit rarely, with serious skin and soft tissue infections, pneumonia and blood poisoning in humans. Pet animals can also be infected with MRSA, where the bacteria first pass from humans to pets and then back to humans. The document noted the importance of basic hygiene measures, especially hand washing before and after contact with animals, and if possible, avoiding direct contact with nasal secretions, saliva and wounds.
The report concluded that as animal movement and contact between live animals and humans are likely to be important factors in the transmission of MRSA, the most effective control measures will be at farm level.
In a parallel review, the European Medicines Agency looked at the risk of colonisation or infection of livestock and companion animals with MRSA in the context of the authorisation and the use of antimicrobial veterinary medicines. The Committee for Medicinal Products for Veterinary Use (CVMP) found that MRSA is resistant to virtually all antibiotics from the beta-lactam group(1), and very often also to other antimicrobials. Prudent use of antimicrobials in animals should remain a key measure and the CVMP recommended monitoring of animal consumption of antimicrobials to identify any sources of unnecessary use. The Committee also recommended that medicines of last resort for MRSA treatment in humans should be avoided in animals, so as to ensure their continued efficacy in humans.
MRSA infections are widespread in hospitals in many EU Member States and are a major cause of hospital-acquired infections which can lead to severe illness and in some cases fatalities. In recent years a link has also been established between MRSA in animals and human MRSA infections. In the areas of the EU where MRSA is found amongst food producing animals, people in contact with these animals, such as farmers, veterinarians and their families, are at risk of acquiring an MRSA infection. Given the severity of some MRSA infection, ECDC is supportive of measures to ensure prudent use of antibiotics in food producing animals. Through the European Antibiotic Awareness Day initiative, ECDC is actively engaged in initiatives to raise awareness about the risks associated with inappropriate use of antibiotics and how to use antibiotics responsibly.
For further information on the work of ECDC, EFSA and EMEA:
1. Beta-lactam antibiotics are a broad class of widely-used antibiotics which include amongst others penicillin derivatives, cephalosporins, monobactams and carbapenems.
Advertise with us - Download World Pharma News' Media Pack Read more
August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information Read more
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, Read more
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in Read more
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving Read more
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better Read more
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: Read more
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 Read more
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth Read more